These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7986117)

  • 1. ["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan].
    Ikeda T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():370-6. PubMed ID: 7986117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Benefits of adjuvant chemotherapy for breast cancer].
    Motomura K; Noguchi S; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1239-44. PubMed ID: 9279342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breast cancer].
    Ikeda T; Jinno H; Matsui A; Mitsui Y; Asaga S; Muto T; Wada M; Kitajima M
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1509-15. PubMed ID: 12355936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant for breast cancer chemo-endocrine therapy].
    Taguchi T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):453-67. PubMed ID: 9530350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in breast cancer chemo-endocrine therapy from the survival standpoint].
    Nomura Y
    Gan To Kagaku Ryoho; 1995 May; 22(6):726-31. PubMed ID: 7755380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Motoki R
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2707-12. PubMed ID: 3137888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment for young women with early breast cancer.
    Balduzzi A; Cardillo A; D'Alessandro C; Colleoni M
    Minerva Ginecol; 2007 Oct; 59(5):513-27. PubMed ID: 17912178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advance in adjuvant therapy for breast cancer].
    Shimizu C; Watanabe T
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of prognostic factors in patients with locally advanced breast cancer treated with intra-arterial infusion chemotherapy as an induction therapy].
    Inaji H; Noguchi S; Yamamoto H; Koyama H; Iwanaga T; Wada A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2910-2. PubMed ID: 2506829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.